Biochemistry and biophysics reports · 2025
Circulating miRNAs combined with AFP improve diagnostic accuracy for HBV-associated hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dieu Hoa Ngo, Giang Dao Phuong, Thu Hien Nguyen Thi, Ngoc Dung Dang Thi, Binh Mai Thanh, Trung Ngo Tat, Thanh Huyen Tran Thi, Tong Hoang Van, Velavan Thirumalaisamy P, Song Le Huu, Hoan Nghiem Xuan
Аннотация
BACKGROUND: Early detection of hepatocellular carcinoma (HCC) remains challenging due to the suboptimal diagnostic accuracy of alpha-fetoprotein (AFP). Circulating microRNAs (miRNAs), given their blood stability and role in cancer biology, have emerged as promising non-invasive biomarkers. This study aimed to assess the diagnostic value of serum miR-21-5p, miR-34a-5p, and miR-30d-3p, individually and in combination with AFP, for distinguishing HBV-related HCC from chronic hepatitis B (CHB) and liver cirrhosis (LC) in a Vietnamese patient cohort.
METHODS: A total of 450 participants were recruited, including 150 patients with HBV-related HCC, 150 with HBV-related LC, and 150 with CHB. Serum miRNA expression levels were quantified using RT-qPCR and were assessed for the diagnostic performance using receiver operating characteristic (ROC) curve.
RESULTS: Expression of circulating miR-21-5p, miR-34a-5p, and miR-30d-3p was significantly upregulated in HCC patients compared to those with CHB and LC (p < 0.001). In which, miR-21-5p presented the highest relative increase, with a 5.43-fold elevation versus CHB. Generalized linear models incorporating single miRNAs (GLM1-3) adjusted for age and gender achieved AUCs = 0.74-0.75 (HCC vs LC); 0.82-0.83 (HCC vs. non-HCC), and 0.9-0.92 (HCC vs. CHB). Notably, the 3-miRNA model adjusted for age and gender (GLM7) demonstrated strong discriminatory power: AUC = 0.92 (HCC vs. CHB), 0.75 (HCC vs. LC), and 0.83 (HCC vs. non-HCC). When AFP was integrated, diagnostic performance improved markedly across all comparisons: AUC = 0.97 (HCC vs. CHB), 0.84 (HCC vs. LC), and 0.91 (HCC vs. non-HCC).
CONCLUSION: Combining circulating miR-21-5p, miR-34a-5p, and miR-30d-3p with AFP significantly enhances diagnostic accuracy for HBV-related HCC, supporting their utility as complementary non-invasive biomarkers for early screening.
METHODS: A total of 450 participants were recruited, including 150 patients with HBV-related HCC, 150 with HBV-related LC, and 150 with CHB. Serum miRNA expression levels were quantified using RT-qPCR and were assessed for the diagnostic performance using receiver operating characteristic (ROC) curve.
RESULTS: Expression of circulating miR-21-5p, miR-34a-5p, and miR-30d-3p was significantly upregulated in HCC patients compared to those with CHB and LC (p < 0.001). In which, miR-21-5p presented the highest relative increase, with a 5.43-fold elevation versus CHB. Generalized linear models incorporating single miRNAs (GLM1-3) adjusted for age and gender achieved AUCs = 0.74-0.75 (HCC vs LC); 0.82-0.83 (HCC vs. non-HCC), and 0.9-0.92 (HCC vs. CHB). Notably, the 3-miRNA model adjusted for age and gender (GLM7) demonstrated strong discriminatory power: AUC = 0.92 (HCC vs. CHB), 0.75 (HCC vs. LC), and 0.83 (HCC vs. non-HCC). When AFP was integrated, diagnostic performance improved markedly across all comparisons: AUC = 0.97 (HCC vs. CHB), 0.84 (HCC vs. LC), and 0.91 (HCC vs. non-HCC).
CONCLUSION: Combining circulating miR-21-5p, miR-34a-5p, and miR-30d-3p with AFP significantly enhances diagnostic accuracy for HBV-related HCC, supporting their utility as complementary non-invasive biomarkers for early screening.